November 23, 2016 - By Marguerite Chambers
Mizuho has cut Valeant Pharma (NYSE:VRX) stock to Underperform in an analyst note sent to investors and clients on Wednesday morning, and has set a 12 month PT at $11. VRX’s old rating was Neutral.
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 2 “Sell”, while 13 “Hold”. This means 35% are positive. $310 is the highest target while $23 is the lowest. The $107.53 average target is 514.11% above today’s ($17.51) stock price. Valeant Pharmaceuticals Intl has been the topic of 79 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The company was maintained on Wednesday, March 16 by Stifel Nicolaus. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, November 17. The rating was maintained by Canaccord Genuity on Wednesday, March 16 with “Hold”. The company was initiated on Friday, October 9 by Mizuho. Mizuho upgraded the stock to “Buy” rating in Tuesday, October 27 report. Mizuho maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Tuesday, March 8. Mizuho has “Neutral” rating and $70 price target. The company was downgraded on Thursday, October 22 by BMO Capital Markets. On Monday, December 14 the stock rating was maintained by RBC Capital Markets with “Outperform”. As per Tuesday, October 20, the company rating was maintained by Scotia Capital. Mizuho downgraded Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Thursday, December 17 to “Neutral” rating.
About 126,149 shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 46.54% since April 21, 2016 and is downtrending. It has underperformed by 51.87% the S&P500.
Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.02, from 0.86 in 2016Q1. The ratio improved, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Pershing Square Mgmt Ltd Partnership, a New York-based fund reported 21.59M shares. Tiaa Cref Invest Management Ltd Liability Com accumulated 571,468 shares or 0.01% of the stock. The California-based Tcw Grp Inc Inc has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Capstone Asset Mngmt reported 26,048 shares or 0.02% of all its holdings. Cmt Asset last reported 0.07% of its portfolio in the stock. Reilly Finance Limited Liability Corporation, a California-based fund reported 70 shares. Wfg Advsr L P, a Texas-based fund reported 2,877 shares. Intact Investment Mgmt Incorporated has 170,800 shares for 0.18% of their US portfolio. Jackson Park Cap Llc accumulated 21,000 shares or 0.58% of the stock. Manchester Cap Mngmt Ltd Company reported 46 shares or 0% of all its holdings. Cacti Asset Management Lc holds 8,400 shares or 0.02% of its portfolio. Glob X Management Ltd Co holds 903 shares or 0% of its portfolio. Creative Planning accumulated 234,055 shares or 0.03% of the stock. The Illinois-based Guggenheim Capital Lc has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Benjamin F Edwards & holds 0% or 105 shares in its portfolio.
Insider Transactions: Since June 9, 2016, the stock had 2 insider buys, and 0 insider sales for $5.04 million net activity. The insider PAPA JOSEPH C bought $4.94 million. Shares for $98,600 were bought by KARABELAS ARGERIS N on Thursday, August 11.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $5.92 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Business.Financialpost.com which released: “Valeant Pharmaceuticals International needs to do a lot more than just cry …” on November 21, 2016, also Fool.com with their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” on November 10, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Investorplace.com and their article: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” published on November 15, 2016 as well as Fool.com‘s news article titled: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” with publication date: November 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.